AVAN Avant Immunotherapeutics (MM)

AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its first quarter 2008 financial results before U.S. financial markets open on Monday, May 19, 2008. AVANT executives will host a conference call and live audio webcast at 10:00 am ET that same day. To access the live call, dial 888-713-4214 (within the United States) or 617-213-4866 (outside the United States). The passcode for participants is 94627424. A replay will be available approximately two hours after the live call. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode I.D. # is 25264226. The replay will also be broadcast via the company�s website www.avantimmune.com approximately two hours after the live call. About AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. is a NASDAQ-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel �targeted immunization� approach. In addition, AVANT is also exploiting its access to proprietary human antibody technology for development of therapeutics monoclonal antibodies (mAbs). AVANT�s deep product pipeline consists of products in varying stages of development, with its lead candidate, CDX-110, currently undergoing evaluation in a Phase 2/3 clinical trial in newly diagnosed glioblastoma multiforme, one of the most aggressive forms of brain cancer. AVANT also has several product candidates in its development pipeline including: CDX-1307, a product based on its proprietary APC Targeting Technology�, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast and colon cancer; TP10, a complement inhibitor, in development for transplantation and other indications; and Three candidates based on its oral, rapidly-protecting, single-dose and temperature-stable vaccine technology, including combination vaccines for travelers, the military and global health needs. AVANT has three commercialized products, including Rotarix� (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs.